Champions Oncology Inc. (CSBR)
NASDAQ: CSBR
· Real-Time Price · USD
6.47
0.09 (1.41%)
At close: Jun 05, 2025, 3:59 PM
6.43
-0.62%
After-hours: Jun 05, 2025, 03:59 PM EDT
Champions Oncology Revenue Breakdown
| Period Ending | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 | Apr 30, 2019 |
|---|---|---|---|---|---|---|
| Personalized Oncology Services Revenue | 18K | 116K | 49K | 166K | 790K | 1.28M |
| Personalized Oncology Services Revenue Growth | -84.48% | +136.73% | -70.48% | -78.99% | -38.14% | n/a |
| Pharmacology Services Revenue | 47.03M | 50.71M | 46.83M | 39.47M | 31.26M | 25.48M |
| Pharmacology Services Revenue Growth | -7.24% | +8.27% | +18.65% | +26.27% | +22.67% | n/a |
| Product and Service, Other Revenue | 3.1M | n/a | n/a | n/a | n/a | n/a |
| Product and Service, Other Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 | Jul 31, 2019 | Apr 30, 2019 | Jan 31, 2019 | Oct 31, 2018 | Jul 31, 2018 | Apr 30, 2018 | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 | Jan 31, 2017 | Oct 31, 2016 | Jul 31, 2016 | Apr 30, 2016 | Jan 31, 2016 | Oct 31, 2015 | Jul 31, 2015 | Apr 30, 2015 | Jan 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.2M | 3.64M | 4.21M | 4.54M | 4.56M | 4.39M | 4.64M | 4.59M | 4.33M | 4.23M | 4.09M | 4.38M | 3.78M | 3.62M | 3.73M | 3.3M | 3.33M | 2.82M | 2.59M | 3.58M | 2.86M | 2.11M | 2.3M | 2.29M | 2.1M | 1.77M | 1.57M | 1.6M | 1.63M | 1.5M | 1.89M | 2.46M | 1.56M | 1.74M | 2.46M | 1.87M | 1.82M | 2.53M | 2.35M | 2.34M | 2.18M |
| Selling, General, and Administrative Revenue Growth | +15.49% | -13.46% | -7.32% | -0.50% | +3.78% | -5.20% | +0.89% | +6.12% | +2.44% | +3.35% | -6.56% | +15.92% | +4.45% | -3.03% | +13.04% | -0.90% | +18.18% | +8.73% | -27.73% | +25.18% | +35.56% | -8.01% | +0.48% | +8.71% | +18.49% | +12.78% | -1.87% | -1.72% | +8.37% | -20.45% | -23.15% | +57.62% | -10.18% | -29.28% | +31.64% | +2.64% | -28.18% | +8.01% | +0.30% | +7.29% | n/a |
| Research and Development Revenue | 1.72M | 1.69M | 1.45M | 2.05M | 2.19M | 2.52M | 2.79M | 2.85M | 3.2M | 2.6M | 2.89M | 2.59M | 2.18M | 2.3M | 2.3M | 2.07M | 1.88M | 1.65M | 1.6M | 1.82M | 1.39M | 1.34M | 1.3M | 1.25M | 1.27M | 1.19M | 1.09M | 1.09M | 1.04M | 1.11M | 1.12M | 1.08M | 998K | 1.01M | 1.21M | 1.18M | 999K | 919K | 1.1M | 1.09M | 1.09M |
| Research and Development Revenue Growth | +1.78% | +16.16% | -29.04% | -6.27% | -13.08% | -9.95% | -2.10% | -10.90% | +22.96% | -9.80% | +11.47% | +18.75% | -5.13% | -0.22% | +11.30% | +10.16% | +13.88% | +3.32% | -12.20% | +30.77% | +3.73% | +2.92% | +4.41% | -1.65% | +6.37% | +9.65% | -0.55% | +4.69% | -6.28% | -0.27% | +3.90% | +7.82% | -0.99% | -16.76% | +2.98% | +17.72% | +8.71% | -16.45% | +1.10% | -0.46% | n/a |
| Sales and Marketing Revenue | 1.81M | 1.75M | 1.68M | 1.78M | 1.8M | 1.79M | 1.7M | 1.85M | 1.76M | 1.7M | 1.69M | 1.61M | 1.55M | 1.64M | 1.57M | 1.47M | 1.49M | 1.35M | 1.21M | 1.09M | 1.31M | 977K | 870K | 918K | 879K | 740K | 518K | 715K | 627K | 551K | 683K | 892K | 726K | 717K | 925K | 757K | 779K | 834K | 1.03M | 943K | 1.09M |
| Sales and Marketing Revenue Growth | +3.14% | +4.29% | -5.46% | -1.17% | +0.11% | +5.84% | -8.27% | +5.00% | +3.59% | +0.47% | +4.77% | +4.26% | -5.55% | +4.19% | +6.93% | -1.34% | +10.68% | +11.59% | +11.03% | -16.76% | +33.78% | +12.30% | -5.23% | +4.44% | +18.78% | +42.86% | -27.55% | +14.04% | +13.79% | -19.33% | -23.43% | +22.87% | +1.26% | -22.49% | +22.19% | -2.82% | -6.59% | -18.95% | +9.12% | -13.80% | n/a |